Ironwood Pharmaceuticals Inc (IRWD) Actualités

Form 8-K - Current report

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in...

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

– New safety and tolerability data show high treatment compliance with apraglutide, low incidence of injection site reactions and adverse events...

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]